Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
Date:11/11/2009

licensure of the current liquid-frozen formulation, but represents an additional business opportunity of major strategic importance. The company expects that the prospective contract will constitute the gateway towards securing additional contracts with the US Government and outside the US as well.

Further detailed PROSTVAC(TM) data presented at the ECCO 15 - 34th ESMO Congress

Further data from the Phase II study with PROSTVAC(TM) were presented at the European CanCer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin in September. The data indicate the potential for a broader therapeutic use of PROSTVAC(TM) in metastatic prostate cancer

Important events after the period

Delivery of IMVAMUNE(R) to Canada completed

As planned, Bavarian Nordic has delivered 20,000 doses of IMVAMUNE(R) to the Canadian government. A pre-New Drug Submission (NDS) meeting with Health Canada (National Regulatory Authority) was held in October 2009 to discuss the potential to file an NDS in 2010 for IMVAMUNE(R) as a safer smallpox vaccine under a Notice of Compliance with Conditions (NOC/C). Conclusions from the meeting have not yet been finalised.

Encouraging data for MVA-BN(R) HIV multiantigen warrant further studies

Bavarian Nordic has completed the analysis of the Phase I/II studies with MVA-BN(R) HIV multiantigen. The final safety and immunogenicity data demonstrate that the vaccine induces a broad T cell response in HIV infected subjects. The high number of responders to the vaccine is encouraging and warrant further studies. Thus, in line with its strategy, Bavarian Nordic is now looking for a partner in order to secure the continued development of MVA-BN(R) HIV multiantigen in a full Phase II.

Bavarian Nordic acquires remaining shares in its subsidiary BN ImmunoTherapeutics Inc. and subsequently own 100% of the subsidiary

Bavarian Nordic has entered into a conditiona
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
2. Bavarian Nordic A/S - Half Year Interim Report 2009
3. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
4. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
5. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
6. Bavarian Nordic Publishes its Annual Results 2008
7. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
8. Bavarian Nordics Case Against Oxford BioMedica
9. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
10. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
11. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Lenexa, KS (PRWEB) April 21, 2015 Contract ... has announced plans to relocate into a new 41,500 ft2 ... XenoTech’s global headquarters, currently located at 16825 W. 116th St. ... and a half times the customized laboratory space, will remain ... where the company was founded more than twenty years ago. ...
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today ... Thursday, April 23, 4:30 p.m. ET. Participants are invited ... Investor call information: U.S./ ... number: (925) 418-7845 Participant Passcode: 32888538 Questions ... , tina.amirkiai@fleishman.com . Access will be ...
(Date:4/21/2015)...  Tute Genomics, a leading provider of cloud-based genomic medicine ... as VP of Marketing. Mr. Forsythe is the latest to ... its commercial operations over the last two quarters. ... is a tremendous addition to the Tute Genomics team," ... Genomics. "Josh,s vast experience commercializing software technology in a highly ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... AMLN ) will be presenting at the FBR ... 28, 2008 at 9:45 a.m. ET / 6:45,a.m. PT. ... Pharmaceuticals, will be providing a corporate overview., The ... a,recording will be made available following the event. The ...
... AstraZeneca (NYSE:,AZN) announced today that it supports ... the company,s latest step to provide the public,with ... Sponsored by Sens. Charles Grassley of Iowa ... a national registry of payments that,biopharmaceutical companies, device ...
... Biosciences,Corporation (Nasdaq: MATK ) announced that it intends ... 2008 on June 4, 2008, at approximately 4:00,p.m. Eastern ... Martek will,conduct a conference call to discuss the results ... interested parties may listen to the call,live via webcast ...
Cached Biology Technology:AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Scientists have been working for more than a ... genes within cells. Now researchers have discovered that microRNA ... each other and ultimately determine the types of cells ... implications in a wide range of fields, including medical ...
... ARBOR, Mich.---As a way to simplify lab-on-a-chip devices ... medical tests, University of Michigan researchers have created ... intelligently route the flow of electricity on computer ... the flow of fluid through their devices without ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-04/sfeb-phr042210.php,">Chinese . A ... extraordinarily complex fluctuations across a wide range of time ... clinical and dynamical significance it may provide warning ... the heart,s pacemaking system. In work published in ...
Cached Biology News:Production of biofuels could benefit by controlling the types of cells that develop in plants 2Microfluidic integrated circuit could help enable home diagnostic tests 2Microfluidic integrated circuit could help enable home diagnostic tests 3Periodic heart rate decelerations in premature infants 2Periodic heart rate decelerations in premature infants 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from a ... human YBX2. (Note: the exact ... Entrez Gene ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
Biology Products: